Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings

被引:82
作者
Hein, G
Weiss, C
Lehmann, G
Niwa, T
Stein, G
Franke, S
机构
[1] Univ Jena, Sect Rheumatol & Osteol, Dept Internal Med 3, D-07740 Jena, Germany
[2] Nagoya Univ Hosp, Dept Clin Prevent Med, Nagoya, Aichi, Japan
关键词
D O I
10.1136/ard.2004.034348
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: The process of bone remodelling is disturbed in the development of osteoporosis. Objective: To investigate if proteins in osteoporotic bone are modified by advanced glycation end products (AGEs), and whether these alterations are related to measures of bone remodelling based on histomorphometric findings. Methods: Bone specimens taken from the iliac crest by bone biopsy of eight osteoporotic patients were investigated by histomorphometry and by immunohistochemical staining with the AGEs imidazolone and N-is an element of-carboxymethyllysine. Results: Both AGEs were found in all bone specimens. The intensity of staining correlated with patient age. The percentage of bone surface covered with osteoblasts showed a significantly negative correlation with the staining intensity of both AGEs. Conclusions: It is known that AGEs can regulate proliferation and differentiation of osteoblastic cells and that AGE-specific binding sites are present in cultured osteoblast-like cells. Moreover, AGE induced biological effects in these cells might be mediated by RAGE (receptor of AGE) or by other AGE receptors in different stages of osteoblast development. The inverse relation between AGE staining intensity and the percentage of bone surface covered with osteoblasts in the trabecular bone may provide evidence that AGE modification of bone proteins disturbs bone remodelling.
引用
收藏
页码:101 / 104
页数:4
相关论文
共 15 条
[1]
Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK) [J].
Cortizo, AM ;
Lettieri, MG ;
Barrio, DA ;
Mercer, N ;
Etcheverry, SB ;
McCarthy, AD .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 250 (1-2) :1-10
[2]
Eriksen E, 1994, BONE HISTOMORPHOMETR, P33
[3]
Advanced glycation end-products pentosidine and Nε-carboxymethyllysine are elevated in serum of patients with osteoporosis [J].
Hein, G ;
Wiegand, R ;
Lehmann, G ;
Stein, G ;
Franke, S .
RHEUMATOLOGY, 2003, 42 (10) :1242-1246
[4]
Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia [J].
Katayama, Y ;
Akatsu, T ;
Yamamoto, M ;
Kugai, N ;
Nagata, N .
JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 (07) :931-937
[5]
Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation [J].
McCarthy, AD ;
Etcheverry, SB ;
Cortizo, AM .
ACTA DIABETOLOGICA, 1999, 36 (1-2) :45-52
[6]
Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress [J].
McCarthy, AD ;
Etcheverry, SB ;
Bruzzone, L ;
Lettieri, G ;
Barrio, DA ;
Cortizo, AM .
BMC CELL BIOLOGY, 2001, 2 (1)
[7]
Miyata T, 1997, J AM SOC NEPHROL, V8, P260
[8]
Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients [J].
Niwa, T ;
Katsuzaki, T ;
Miyazaki, S ;
Miyazaki, T ;
Ishizaki, Y ;
Hayase, F ;
Tatemichi, N ;
Takei, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1272-1280
[10]
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses [J].
Schmidt, AM ;
Du Yan, S ;
Yan, SF ;
Stern, DM .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (07) :949-955